Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells

Metastatic Colonization Requires the Repression of the Epithelial-Mesenchymal Transition Inducer Prrx1

(2012) Oscar H. Ocaña et al.   CANCER CELL

Novel Aspects of Mevalonate Pathway Inhibitors as Antitumor Agents

(2012) M. Thurnher et al.   CLINICAL CANCER RESEARCH

Effects of Bone-Targeted Agents on Cancer Progression and Mortality

(2012) R. Coleman et al.   JNCI-Journal of the National Cancer Institute

TNFα-Induced Apoptosis Enabled by CCN1/CYR61: Pathways of Reactive Oxygen Species Generation and Cytochrome c Release

(2012) Vladislava Juric et al.   PLoS One

CCL11 (eotaxin-1): A new diagnostic serum marker for prostate cancer

(2012) Manisha Agarwal et al.   PROSTATE

MYC and Metastasis

(2011) A. Wolfer et al.   CANCER RESEARCH

Pathways of chemotherapy resistance in castration-resistant prostate cancer

(2011) K. L. Mahon et al.   ENDOCRINE-RELATED CANCER

Emerging Therapies to Prevent Skeletal Morbidity in Men With Prostate Cancer

(2011) Philip J. Saylor et al.   JOURNAL OF CLINICAL ONCOLOGY

Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle?

(2011) Jones T. Nauseef et al.   Nature Reviews Urology

Prognostic relevance of Bcl-2 overexpression in surgically treated prostate cancer is not caused by increased copy number or translocation of the gene

(2011) A. Fleischmann et al.   PROSTATE

HAb18G/CD147 cell-cell contacts confer resistance of a HEK293 subpopulation to anoikis in an E-cadherin-dependent manner

(2010) Xiao-Kui Ma et al.   BMC CELL BIOLOGY

Biochemical and molecular mechanisms of action of bisphosphonates

(2010) Michael J. Rogers et al.   BONE

Metronomic administration of Zoledronic Acid and Taxotere combination in castration resistant prostate cancer patients: Phase I ZANTE trial

(2010) Gaetano Facchini et al.   CANCER BIOLOGY & THERAPY

HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT

(2010) Francesca Bruzzese et al.   JOURNAL OF CELLULAR PHYSIOLOGY

p38 Mitogen-Activated Protein Kinase Promotes Cell Survival in Response to DNA Damage but Is Not Required for the G2 DNA Damage Checkpoint in Human Cancer Cells

(2010) M. S. Phong et al.   MOLECULAR AND CELLULAR BIOLOGY

Translational Activation of Snail1 and Other Developmentally Regulated Transcription Factors by YB-1 Promotes an Epithelial-Mesenchymal Transition

(2009) Valentina Evdokimova et al.   CANCER CELL

Emerging roles of chemokines in prostate cancer

(2009) David Vindrieux et al.   ENDOCRINE-RELATED CANCER

VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop

(2009) Oscar Gonzalez-Moreno et al.   EXPERIMENTAL CELL RESEARCH

Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells

(2009) Monica Marra et al.   INTERNATIONAL JOURNAL OF CANCER

Mechanical Regulation of the Proangiogenic Factor CCN1/CYR61 Gene Requires the Combined Activities of MRTF-A and CREB-binding Protein Histone Acetyltransferase

(2009) Mary Hanna et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis

(2009) F. Bruzzese et al.   MOLECULAR CANCER THERAPEUTICS

Ezrin mediates c-Myc actions in prostate cancer cell invasion

(2009) Y-C Chuan et al.   ONCOGENE

Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells

(2008) B. Ory et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE